"Computer driven prediction of immunogenic potential is useful for improving the design and development of monoclonal antibodies, therapeutic proteins and other protein based products such as vaccines."

EpiVax Inc. has developed a suite of bioinformatics tools and techniques for use in designing effective therapeutics for smallpox, AIDS, TB, cancer and other diseases. The company is applying the principles of computer modeling, gene sequencing and molecular immunology to the development of vaccines and to the modification of protein-based drugs-- modeling how proteins from vaccines and therapeutic proteins interface with the immune system on the cellular level. EpiVax’s technology currently makes it possible to identify the components that allow the various molecular parts of the immune system to fit together to spark host immune response. Clients include Amgen, Lilly, and Biosynexus.

Additional information is available at www.epivax.com.

<< Back to Brown in the Marketplace main page